This Phase I, randomised, triple-masked, crossover trial (n=20) will assess the acute analgesic effects of oral MDMA in healthy adults aged 18 to 75 years. It will compare MDMA 25 mg, 75 mg and 125 mg with placebo to evaluate whether MDMA reduces experimentally induced acute nociceptive pain, hyperalgesia and allodynia. Participants will receive the study drug by mouth during a validated electrical stimulation pain model in which repeated small electrical pulses are applied under the skin to produce moderate pain and secondary pain phenomena. The main outcome is periprocedural pain measured with the numerical rating scale, with the highest MDMA dose compared against the lower doses and placebo.
This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect).
In the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.